Zuidwest Radiotherapeutisch Instituut

What Zuidwest Radiotherapeutisch Instituut does

Zuidwest Radiotherapeutisch Instituut (ZRTI) is a Dutch non-profit radiotherapy foundation founded in 1981, headquartered in Vlissingen with a second location in Roosendaal. The institution is the legal entity 'Stichting Zuidwest Radiotherapeutisch Instituut', holds ANBI-status (Algemeen Nut Beogende Instelling), is governed by a Raad van Bestuur chaired by Bestuurder Peter Jongens with a Raad van Toezicht under chairperson Annechien Broekmeijer, and operates with more than 100 employees across the two sites. It is regulated and reimbursed under the Dutch healthcare framework (Zorgverzekeringswet and WLZ) with tariffs set by the Nederlandse Zorgautoriteit (NZa), and it maintains NEN-7510 information security certification, audited annually.

The core offering is high-quality radiotherapy (bestraling) for cancer patients, delivered through a structured seven-step treatment pathway covering registration, consultation, information session, CT-scan, radiation planning, radiation treatment, and follow-up control. Indication coverage includes bladder, breast, bone, rectal, gynecological, head and neck, skin, lung, prostate, and esophageal cancers, with approximately 2,000 patients treated annually. Patient-facing digital services include the 'Mijn ZRTI' portal and integration with the national Persoonlijke Gezondheidsomgeving (PGO) infrastructure. Technology stack is conventional linear-accelerator radiotherapy with CT-based planning; no proprietary AI or software products are disclosed.

ZRTI generates revenue exclusively from reimbursed healthcare services for referred cancer patients, with ~2,000 patients per year flowing through GP and specialist referral channels from general and academic hospitals in Zeeland, West-Brabant, and parts of Zuid-Holland. Patients pay only per their insurance policy terms for covered treatments; uninsured or partially insured patients may be asked for deposits. Distribution is direct via hospital and specialist referral plus a structured direct intake process. Marketing is light-touch professional healthcare: website (zrti.nl), Facebook, LinkedIn, Instagram, and digital newsletters. An affiliated foundation, Stichting Vrienden van het ZRTI, raises donations in support of patient care activities; this is a minor adjacent funding stream rather than primary revenue.

Name

Zuidwest Radiotherapeutisch Instituut

Legal name

Stichting Zuidwest Radiotherapeutisch Instituut

Website

https://zrti.nl

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

51–100 employees

Short description

Zuidwest Radiotherapeutisch Instituut (ZRTI) is a Dutch non-profit foundation operating radiotherapy centers in Vlissingen and Roosendaal, delivering reimbursed radiation treatment to approximately 2,000 cancer patients per year across Zeeland, West-Brabant, and parts of South-Holland.

Ownership category

akta.pro rank

Product category

Radiation Oncology Services

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK)

Keywords

• Radiation oncology services
• Cancer radiotherapy treatment
• External beam radiotherapy
• Radiation therapy center
• Oncology care services

Headquarters

HQ city

Vlissingen

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Others

Revenue model

1. Healthcare Services - Radiotherapy Treatment: ZRTI provides radiotherapy (radiation therapy) services for cancer patients. Services are funded through the Dutch health insurance system (Zorgverzekeringswet) and WLZ (Wet langdurige zorg). Patients with statutory payment authorization receive care covered by their health insurance. The institution operates as a non-profit foundation.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

ZRTI provides high-quality radiotherapy (radiation therapy) services for cancer patients at two clinical locations in Roosendaal and Vlissingen, serving the Zeeland, West-Brabant and parts of South-Holland regions of the southwestern Netherlands. The center treats approximately 2,000 patients annually across cancer types including bladder, breast, bone, rectal, gynecological, head and neck, skin, lung, prostate and esophageal cancers. Each patient follows a structured seven-step treatment pathway (aanmelden, consult, voorlichting, CT-scan, bestralingsplan, bestralingen, controle & vervolg) covered by Dutch statutory health insurance.

Product overview

Zuidwest Radiotherapeutisch Instituut (ZRTI) is a radiotherapy center providing high-quality radiation treatment for cancer patients. The organization operates as a single facility with two locations (Roosendaal and Vlissingen) offering a comprehensive treatment route spanning seven steps from registration through follow-up. ZRTI provides specialized radiotherapy treatments for various cancer types including bladder, breast, bone, rectal, gynecological, head/neck, skin, lung, prostate, and esophageal cancers. The institution also provides patient-facing digital services including the Mijn ZRTI patient portal and integration with Personal Health Environments (PGO).

Differentiator

Problem solved

Functional benefit

Products and services

• Radiotherapie (Radiotherapy) High-quality radiotherapy (radiation) treatment for cancer patients, delivered at locations in Roosendaal and Vlissingen to patients in the Zeeland and West-Brabant region. The service covers radiation therapy for cancer types including bladder, breast, bone, rectal, gynecological, head and neck, skin, lung, prostate and esophageal cancers, and is delivered through a structured seven-step treatment pathway.
• Radiotherapy for Bladder Cancer Specialized radiotherapy treatment pathway for patients diagnosed with bladder cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Breast Cancer Specialized radiotherapy treatment pathway for patients diagnosed with breast cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Bone Cancer Specialized radiotherapy treatment pathway for patients diagnosed with bone cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Rectal Cancer Specialized radiotherapy treatment pathway for patients diagnosed with rectal (endeldarm) cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Gynecological Cancer Specialized radiotherapy treatment pathway for patients with gynecological cancers, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Head and Neck Cancer Specialized radiotherapy treatment pathway for patients diagnosed with head and neck cancers, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Skin Cancer Specialized radiotherapy treatment pathway for patients diagnosed with skin cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Lung Cancer Specialized radiotherapy treatment pathway for patients diagnosed with lung cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Prostate Cancer Specialized radiotherapy treatment pathway for patients diagnosed with prostate cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Radiotherapy for Esophageal Cancer Specialized radiotherapy treatment pathway for patients diagnosed with esophageal (slokdarm) cancer, provided as part of the ZRTI cancer-type treatment portfolio.
• Mijn ZRTI (Patient Portal) Online patient portal offered by ZRTI allowing patients to access their personal health information and manage appointments related to their radiotherapy treatment.
• Persoonlijke Gezondheidsomgeving (PGO) Integration Personal Health Environment (PGO) integration that enables ZRTI patients to view their ZRTI health data within their own chosen PGO application or website, supporting national interoperability of health records.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered minor and core.

• Nederlandse Kankerregistratie (NKR)minorOthersZRTI shares patient data with the Dutch Cancer Registration (NKR) for independent research purposes as required by law.
• Inspectie Gezondheidszorg en Jeugd (IGJ)minorOthersZRTI provides quality indicators from the medical specialist care quality indicator set to the Dutch Health and Youth Care Inspectorate.
• Dutch Institute for Clinical Auditing (DICA)minorOthersZRTI participates in clinical auditing through DICA for quality assurance purposes.
• General and academic hospitals (specialists)coreStrategic or Co-development PartnerZRTI collaborates with specialists from general and academic hospitals for comprehensive cancer care. This collaboration ensures patients receive integrated care combining radiotherapy with other treatment modalities as needed.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Others

• Elekta: Elekta is a Swedish manufacturer of linear accelerators, brachytherapy systems, and oncology software. Like Varian, Elekta is a primary equipment vendor for radiotherapy centers, making it an enabling peer whose technology decisions influence ZRTI's modality mix and operating costs.
• Varian Medical Systems (Siemens Healthineers): Varian is a leading global manufacturer of linear accelerators, treatment planning software, and radiotherapy informatics used by ZRTI. As a key technology supplier to ZRTI, it is an adjacent peer whose product roadmap and pricing directly shape ZRTI's clinical capabilities and capex.
• Bayer (radioligand therapy / Xofigo): Bayer's radiopharmaceutical franchise (e.g., Xofigo and broader targeted radionuclide therapies) represents the systemic, non-radiotherapy alternative to external-beam radiation that competes for the same patient population. As a developer of radioligand therapies, Bayer signals the disruptive treatment modalities that could affect ZRTI's long-term demand.

Direct peers

• Maastro: Maastro is a Dutch radiotherapy institute in Maastricht offering radiation oncology services to cancer patients in Limburg and surrounding regions. Like ZRTI, it is a dedicated, non-academic radiotherapy provider serving a defined regional catchment with multi-modality treatment capability.
• Radiotherapiegroep: Radiotherapiegroep operates multiple radiotherapy clinics in the Netherlands (Arnhem, Apeldoorn, Deventer, Ede), delivering radiation treatment for various cancers. It is a direct regional peer to ZRTI, operating a multi-site model of dedicated outpatient radiation oncology centers.

Emerging players

• HollandPTC: HollandPTC is a Dutch proton therapy center in Delft that offers an advanced alternative to conventional radiotherapy for specific cancer indications. It is comparable to ZRTI as a Dutch radiotherapy provider, though it competes in a narrower, higher-acuity segment using a different modality.

Broad incumbents

• Netherlands Cancer Institute (NKI/AVL): NKI/AVL is a leading Dutch comprehensive cancer center combining research, medical oncology, surgery, and radiotherapy. While ZRTI is a focused regional radiotherapy provider, NKI sets the clinical standard and competes for complex cases in the broader Dutch oncology ecosystem.
• UMC Utrecht Cancer Center: UMC Utrecht's cancer center combines radiotherapy with medical oncology and research at an academic level. It represents the broader oncology incumbent against which regional providers like ZRTI differentiate on access and proximity.
• Erasmus MC Cancer Institute: Erasmus MC's cancer center in Rotterdam is an academic comprehensive oncology provider that includes a radiotherapy department. As a large academic institution, it offers broader oncology services and competes with ZRTI for referrals from the South-Holland portion of ZRTI's catchment.
• GenesisCare: GenesisCare is a large international operator of oncology and radiotherapy clinics across Europe and Australia. While not active in the Netherlands today, it is a benchmark peer for scale, multi-site radiotherapy operations, and value-based care models relevant to ZRTI's growth strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/zuidwestradiotherapeutischinstituut/?viewAsMember=true
• Instagraminstagram.com/zrtivlissingenroosendaal

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zuidwest Radiotherapeutisch Instituut